Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Endocrinology and Metabolism ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Acromegaly.N Engl J Med. 1990; 322: 966-977
- Systemic complications of acromegaly: epidemiology, pathogenesis, and management.Endocr Rev. 2004; 25: 102-152
- Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA).Eur J Endocrinol. 2004; 151: 439-446
- Factors influencing mortality in acromegaly.J Clin Endocrinol Metab. 2004; 89: 667-674
- A meta-analysis of the effect of lowering serum levels of GH and IGF-1 on mortality in acromegaly.Eur J Endocrinol. 2008; 159: 89-95
- Predictors of morbidity and mortality in acromegaly: an Italian survey.Eur J Endocrinol. 2012; 167: 189-198
- Cardiovascular events in acromegaly: distinct role of Agatston and Framingham score in the 5-year prediction.Endocrine. 2014; 47: 206-212
- Cardiac involvement in acromegaly: specific myocardiopathy or consequence of systemic hypertension?.J Clin Endocrinol Metab. 1997; 82: 1047-1053
- Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy.J Clin Endocrinol Metab. 2000; 85: 193-199
- Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic.J Clin Endocrinol Metab. 2014; 99: 4438-4446
- Mortality in acromegaly: a 20-year follow-up study.Endocr Relat Cancer. 2015; 23: 469-480
- Treatments, complications, and healthcare utilization associated with acromegaly: a study in two large United States databases.Pituitary. 2014; 17: 333-341
- AcroBel the Belgian registry on acromegaly: a survey of the 'real-life' outcome in 418 acromegalic subjects.Eur J Endocrinol. 2007; 157: 399-409
- Acromegaly: presentation, morbidity and treatment outcomes at a single centre.Int J Clin Pract. 2011; 65: 896-902
- Epidemiology, treatment trends and outcomes of acromegaly.Eur J Intern Med. 2012; 23: e206-e207
- Emerging trends in the diagnosis and treatment of acromegaly in Canada.Clin Endocrinol (Oxf). 2013; 79: 79-85
- The incidence and prevalence of acromegaly, a nationwide study from 1955 through 2013.Pituitary. 2015; 18: 803-807
- Acromegaly incidence, prevalence, complications and long-term prognosis: a nationwide cohort study.Eur J Endocrinol. 2016; 175: 181-190
- The Mexican acromegaly registry: clinical and biochemical characteristics at diagnosis and therapeutic outcomes.J Clin Endocrinol Metab. 2016; 101: 3997-4004
- Long-term treatment outcomes of acromegaly patients presenting biochemically-uncontrolled at a tertiary pituitary center.BMC Endocr Disord. 2017; 17: 49
- Comorbidities, treatment patterns and cost-of-illness of acromegaly in Sweden: a register-linkage population-based study.Eur J Endocrinol. 2017; 176: 203-212
- Incidence of myocardial infarction and stroke in acromegaly patients: results from the German Acromegaly Registry.Pituitary. 2017; 20: 635-642
- Changes in the management and comorbidities of acromegaly over three decades: the French Acromegaly Registry.Eur J Endocrinol. 2017; 176: 645-655
- Prevalence of hypertension in acromegalic patients: clinical measurement versus 24-hour ambulatory blood pressure monitoring.Clin Endocrinol (Oxf). 1998; 48: 149-152
- Role of ambulatory blood pressure monitoring in patients with acromegaly.J Hypertens. 2016; 34: 1357-1363
- Hypertension in acromegaly: hereditary hypertensive factor produces hypertension by enhancing IGF-I production.Endocr J. 1995; 42: 781-787
- Hypertension in acromegaly and in the normal population: prevalence and determinants.Clin Endocrinol (Oxf). 2005; 63: 470-476
- Revisiting the relationship between blood pressure and insulin-like growth factor-1.Hypertension. 2014; 63: 1070-1077
- Cardiovascular disease and sleep disordered breathing in acromegaly.Neuroendocrinology. 2016; 103: 75-85
- Disease activity and lifestyle influence comorbidities and cardiovascular events in patients with acromegaly.Eur J Endocrinol. 2016; 175: 443-453
- A consensus on the diagnosis and treatment of acromegaly complications.Pituitary. 2013; 16: 294-302
- Twenty-four hour profile of blood pressure in patients with acromegaly. Correlation with demographic, clinical and hormonal features.J Endocrinol Invest. 1999; 22: 48-54
- The beneficial effect of acromegaly control on blood pressure values in normotensive patients.Clin Endocrinol. 2014; 81: 573-581
- Growth Hormone, the insulin-like growth factor system, and the kidney.J Clin Endocrinol Metab. 1996; 5: 423-480
- Growth hormone receptor messenger ribonucleic acid in normal and pathologic human adrenocortical tissues—An analysis by quantitative polymerase chain reaction technique.J Clin Endocrinol Metab. 1997; 82: 2671-2676
- Epithelial sodium channel is a key mediator of growth hormone induced sodium retention in acromegaly.Endocrinology. 2008; 149: 3294-3305
- Body fluid expansion in acromegaly is related to enhanced epithelial sodium channel (ENaC) activity.J Clin Endocrinol Metab. 2011; 96: 2127-2135
- Chronic growth hormone excess is associated with increased aldosterone: a study in patients with acromegaly and in growth hormone transgenic mice.Exp Biol Med (Maywood). 2009; 234: 1002-1009
- Insulin-like growth factor I administration induces fluid and sodium retention in healthy adults: Possible involvement of renin and atrial natriuretic factor.Clin Endocrinol (Oxf). 2000; 52: 181-186
- Acromegaly and hypertension: Prevalence and relationship to the renin-angiotensin-aldosterone system.Klin Wochenschr. 1990; 68: 583-587
- Effect of sodium depletion on the renin-angiotensin-aldosterone system and renal prostaglandins in acromegalic patients.Exp Clin Endocrinol. 1990; 96: 213-218
- CYP11B2-344T/C Gene Polymorphism and Blood Pressure in Patients with Acromegaly.J Clin Endocrinol Metab. 2006; 91: 5008-5012
- Association between ACE and AGT polymorphism and cardiovascular risk in acromegalic patients.Pituitary. 2017; 20: 569-577
- Basal and saline-stimulated levels of plasma atrial natriuretic factor in acromegaly.Clin Endocrinol. 1989; 31: 431-438
- Sodium-retaining effect of insulin in diabetes.Am J Physiol Regul Integr Comp Physiol. 2012; 303: R1101-R1109
- High blood pressure and hyperinsulinaemia in acromegaly and in obesity.Clin Exp Hypertens. 1989; A11: 407-425
- Correlation between blood pressure and plasma insulin in acromegaly.J Intern Med. 1993; 234: 61-63
- Acromegaly. Clinical and biochemical features in 500 patients.Medicine (Baltimore). 1994; 73: 233-240
- Relationship between blood pressure and glucose tolerance in acromegaly.Clin Endocrinol (Oxf). 2001; 54: 189-195
- Pathogenesis and prevalence of hypertension in acromegaly.Pituitary. 2001; 4: 239-249
- The sympathetic nervous system alterations in human hypertension.Circ Res. 2015; 116: 976-990
- Diurnal rhythm of plasma catecholamines in acromegaly.J Clin Endocrinol Metab. 1999; 84: 2458-2467
- Hypertension is Common in Patients with Newly Diagnosed Acromegaly and is Independently Associated with Renal Resistive Index.High Blood Press Cardiovasc Prev. 2019; 26: 69-75
- Insulin and insulin-like growth factor-I promotes angiotensinogen production and growth in vascular smooth muscle cells.J Hypertens. 2000; 18: 1051-1056
- Acromegalic patients show the presence of hypertrophic remodeling of subcutaneous small resistance arteries.Hypertension. 2004; 43: 561-565
- Small vessel remodeling and impaired endothelial-dependent dilatation in subcutaneous resistance arteries from patients with acromegaly.J Clin Endocrinol Metab. 2009; 94: 1111-1117
- Vascular reactivity in acromegalic patients: preliminary evidence for regional endothelial dysfunction and increased sympathetic vasoconstriction.Clin Endocrinol (Oxf). 2000; 53: 445-451
- Reduced nitric oxide levels in acromegaly: cardiovascular implications.Blood Press. 2005; 14: 227-232
- Impairment in flow-mediated vasodilatation of the brachial artery in acromegaly.Med Princ Pract. 2009; 18: 228-232
- Arterial properties in acromegaly: relation to disease activity and associated cardiovascular risk factors.Pituitary. 2016; 19: 322-331
- Oxidative stress and reduced antioxidative status, along with endothelial dysfunction in acromegaly.Horm Metab Res. 2013; 45: 314-318
- Higher growth hormone levels are associated with erectile dysfunction in male patients with acromegaly.Endocr Pract. 2019; 25: 562-571
- Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases.Diabetes Metab Res Rev. 2006; 22: 423-436
- Altered circadian blood pressure profile in patients with active acromegaly. Relationship with left ventricular mass and hormonal values.J Hum Hypertens. 2001; 15: 601-605
- Endocrine aspects of obstructive sleep apnea.J Clin Endocrinol Metab. 2010; 95: 483-495
- Sleep apnea in acromegaly: a review on prevalence, pathogenetic aspects and treatment.Expert Rev Endocrinol Metab. 2012; 7: 55-62
- Obstructive sleep apnoea syndrome as a risk factor for hypertension: Population study.BMJ. 2000; 320: 479-482
- Obstructive sleep apnoea and its cardiovascular consequences.Lancet. 2009; 373: 82-93
- Renin-angiotensin system blockade improves cardiac indices in acromegaly patients.Exp Clin Endocrinol Diabetes. 2017; 125: 365-367
- GH and IGF-I excess control contributes to blood pressure control: results of an observational, retrospective, multicentre study in 105 hypertensive acromegalic patients on hypertensive treatment.Clin Endocrinol (Oxf). 2008; 69: 613-620
- Persistence of diabetes and hypertension after multimodal treatment of acromegaly.J Clin Endocrinol Metab. 2018; 103: 2369-2375
- Acromegaly: an endocrine society clinical practice guideline.J Clin Endocrinol Metab. 2014; 99: 3933-3951
- Postoperative changes in metabolic parameters of patients with surgically controlled acromegaly: assessment of new stringent cure criteria.Neurol Med Chir (Tokyo). 2018; 58: 147-155
- Impact of successful transsphenoidal surgery on cardiovascular risk factors in acromegaly.Eur J Endocrinol. 2003; 148: 193-201
- Marked improvement in cardiovascular function after successful transsphenoidal surgery in acromegalic patients.Clin Endocrinol (Oxf). 2001; 55: 307-313
- Prospective study of surgical treatment of acromegaly: effects on ghrelin, weight, adiposity, and markers of CV risk.J Clin Endocrinol Metab. 2014; 99: 4124-4132
- Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy.J Clin Endocrinol Metab. 2008; 93: 2639-2646
- Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegaly.J Clin Endocrinol Metab. 2004; 89: 658-661
- Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis.J Clin Endocrinol Metab. 2014; 99: 1825-1833
- Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.Lancet Diabetes Endocrinol. 2014; 2: 875-884
- Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors.J Clin Endocrinol Metab. 2006; 91: 121-128
- Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly.J Clin Endocrinol Metab. 2001; 86: 2779-2786
- Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis.J Clin Endocrinol Metab. 2007; 92: 1743-1747
- Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study.J Clin Endocrinol Metab. 2009; 94: 3746-3756
- Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.N Engl J Med. 2000; 342: 1171-1177
- Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist.Lancet. 2001; 358: 1754-1759
- ACROSTUDY: the Italian experience.Endocrine. 2015; 48: 334-341
- How to improve effectiveness of pegvisomant treatment in acromegalic patients.J Endocrinol Invest. 2017; 41: 575-581
- First report on persistent remission of acromegaly after withdrawal of long-term pegvisomant monotherapy.Growth Horm IGF Res. 2019; 45: 17-19
- Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.Eur J Endocrinol. 2006; 154: 467-477
- Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance.J Clin Endocrinol Metab. 2007; 92: 476-482
- The treatment with growth hormone receptor antagonist in acromegaly: effect on vascular structure and function in patients resistant to somatostatin analogues.J Endocrinol Invest. 2010; 33: 663-670
- Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly.Endocrine. 2017; 55: 872-884
- Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly: comparison with matched data from the general population and the effect of disease control.J Clin Endocrinol Metab. 2010; 95: 3648-3656
- Changes in metabolic parameters and cardiovascular risk factors after therapeutic control of acromegaly vary with the treatment modality. Data from the Bicêtre cohort, and review of the literature.Endocrine. 2019; 63: 348-360
Article info
Publication history
Published online: September 17, 2019
Footnotes
Conflicts of interest: S. Puglisi has no conflicts of interest in connection with this article. M. Terzolo has received research grants from Novartis.
Identification
Copyright
© 2019 Elsevier Inc. All rights reserved.
